PYFAESTHETIC Joins AMUSE 2025, Introduces the Latest Synthetic Small Extracellular Vesicles Technology in Skincare
Jakarta, June 26, 2025 — Amid the growing public awareness of the importance of safe, scientific, and low-risk skincare, synthetic biotechnology-based innovations have become a major focus in the field of aesthetic medicine. In response to this trend, PYFAESTHETIC, the aesthetic business unit of PT Pyridam Farma Tbk (PYFAGROUP), participated in the Aesthetic Medicine Update & Scientific Exhibition (AMUSE) 2025, held on June 20–22, 2025, at ICE BSD, South Tangerang.
AMUSE 2025 is an international-level aesthetic medicine congress organized by the Jakarta Science Academy. With the theme “Aesthetic Uncovered: A Purely Scientific Congress,” the event is designed as a purely educational platform—free from commercial influence—and focused on evidence-based discussions. Over 1,200 doctors and experts in dermatology, plastic surgery, and aesthetics gathered over the three-day event to attend presentations, masterclasses, live demos, and networking sessions with 40+ exhibitors showcasing the latest technologies and techniques in aesthetic medicine.
PYFAESTHETIC joined the event through an interactive booth and two scientific symposium sessions, “Optimizing Acne Outcomes” and “Synthetic Small Extracellular Vesicles in Aesthetics,” as part of the company’s commitment to advancing technology and education in aesthetic medicine.
A key highlight was the symposium titled “Synthetic Small Extracellular Vesicles in Aesthetics: Innovation and the Future of Treatment,” featuring keynote speaker Dr. Reeza Edward, Sp.DVE, an experienced specialist in Dermatology, Venereology, and Aesthetics, widely known for his expertise in facial anatomy-based skincare treatments. The session discussed how small synthetic vesicle technology offers a new approach to more targeted and low-risk aesthetic procedures. Facial anatomy was also reviewed to help doctors achieve more optimal treatment outcomes.
The technology introduced in this symposium relies on synthetic small extracellular vesicles (sEVs)—synthetic particles that mimic natural cellular communication within the skin. This technology can be supported by active ingredients such as biomimetic peptides, niacinamide, sodium hyaluronate, glycine, proline, and antioxidants that work synergistically to aid skin regeneration, improve texture, maintain firmness, and even out skin tone. This product is also suitable for all skin types, including sensitive skin, as it contains no animal-derived or biological components.
The use of Synthetic Small Extracellular Vesicle-based technology is becoming increasingly relevant in Indonesia, in line with growing demand for scientifically researched skincare. This reflects a shift in preference from biological materials to more stable and controllable synthetic formulations.
“PYFAESTHETIC is committed not only to delivering innovative products but also to actively enhancing the capabilities of Indonesian doctors through training both domestically and abroad. We believe the synergy between technology and education will establish a new standard for safer and more sustainable aesthetic practices,” said Wila Lesthia Kharisma, Head of Marketing at PYFAESTHETIC.
As part of the event, PYFAESTHETIC also officially introduced NEOFOUND BIOS, its latest product with the tagline “Next-Generation, Skin Revitalization.” Featuring synthetic sEVs technology, NEOFOUND BIOS offers an effective solution for skin revitalization, supporting skin regeneration, maintaining collagen and elastin for elasticity, and evening out skin tone—making it an ideal choice for patients of all skin types.
Through the launch of NEOFOUND BIOS and the educational approach brought to AMUSE 2025, PYFAESTHETIC strengthens its strategic role as a trusted partner for medical professionals in Indonesia. Moving forward, PYFAESTHETIC will continue to deliver innovative technologies and competency development programs to promote more competitive and internationally standardized aesthetic practices.
About PYFAGROUP
PT Pyridam Farma Tbk (“PYFA”), known by the brand PYFAGROUP, is a public pharmaceutical company listed on the Indonesia Stock Exchange (Ticker: PYFA). PYFA operates business units producing prescription drugs in various forms such as tablets, capsules, creams, and injections. PYFA is the controlling shareholder of several subsidiaries, including PT Holi Pharma (based in Cimahi, West Java), PT Ethica Industri Farmasi (based in Cikarang, West Java), and Probiotec Pty Ltd (based in Australia).
About PYFAESTHETIC
PYFAESTHETIC is a business unit of PYFA focused on dermatology and aesthetics, offering a range of international aesthetic products registered with BPOM and the Ministry of Health, including skincare, fillers, and beauty devices for professional practitioners. In addition to product distribution, PYFAESTHETIC actively conducts professional training, including cadaver training abroad. With its commitment to quality, education, and collaboration, PYFAESTHETIC serves as a strategic partner for global aesthetic brands to enter the Indonesian market and support the development of the aesthetic industry in Southeast Asia.
Media Contact:
Leilanie Nadia Kusuma
Website: www.pyfa.co.id
Email: corcomm@pyfa.co.id
